IMMUNOPROLIFERATIVE DISORDERS
Clinical trials for IMMUNOPROLIFERATIVE DISORDERS explained in plain language.
Never miss a new study
Get alerted when new IMMUNOPROLIFERATIVE DISORDERS trials appear
Sign up with your email to follow new studies for IMMUNOPROLIFERATIVE DISORDERS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells get a navigation system to hunt down lymphoma
Disease control OngoingThis early-phase study tests a new treatment for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has not responded to standard therapy or has returned. The treatment uses a patient's own immune cells (T cells) that are genetically modified to recognize and attack c…
Matched conditions: IMMUNOPROLIFERATIVE DISORDERS
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 17, 2026 05:05 UTC
-
Engineered immune cells with 'Sleep Switch' tested for tough leukemia
Disease control OngoingThis study tests a new treatment for people with a type of leukemia that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to better find and kill leukemia cells. A special safety switch is a…
Matched conditions: IMMUNOPROLIFERATIVE DISORDERS
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:04 UTC
-
Engineered immune cells with 'Kill Switch' offer new hope for lymphoma patients
Disease control OngoingThis early-phase study tests a new type of CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. The T-cells are engineered to recognize and attack cancer cells, but also include a safety switch that can be activated to reduce severe…
Matched conditions: IMMUNOPROLIFERATIVE DISORDERS
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
Supercharged immune cells take aim at tough lymphomas
Disease control OngoingThis study is testing a new cell therapy for people with Hodgkin's or Non-Hodgkin's lymphoma that has come back or hasn't responded to other treatments. Doctors take a patient's own immune cells, modify them in a lab to better target cancer, and then infuse them back. The main go…
Matched conditions: IMMUNOPROLIFERATIVE DISORDERS
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC